Irinotecan Onkovis

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Onkovis, is a topoisomerase I inhibitor presented as an injection for intravenous use. It is employed in the treatment of colorectal cancer and metastatic colorectal cancer in adult patients, often as part of combination chemotherapy regimens designed to improve response rates and survival outcomes.

GNH USA supplies Irinotecan Onkovis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring quality‑assured product delivery across regulated markets through reliable logistics.

Irinotecan, a topoisomerase I inhibitor, is used in colorectal cancer treatment pathways.

Colorectal cancer: used as part of combination chemotherapy to reduce tumor size and improve survival. Metastatic colorectal cancer: administered to control disease spread and prolong life in patients with advanced disease. Advanced colorectal cancer: employed when disease is not resectable to lessen tumor burden and alleviate symptoms.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: frequent loose stools that may become severe. - Nausea and vomiting: gastrointestinal upset common during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: intense inflammation of the colon causing dehydration. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

When using Irinotecan, clinicians should observe several precautionary measures to minimize risks.

- Monitor blood counts: perform complete blood count regularly to detect neutropenia early. - Assess liver function: check hepatic enzymes before and during therapy to adjust dosing if needed. - Maintain hydration: ensure adequate fluid intake to reduce severity of diarrhea. - Avoid strong CYP3A4 inhibitors: concurrent use may increase irinotecan exposure and toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise irinotecan levels and increase toxicity. - Carboplatin: combined use can intensify myelosuppression. - Live vaccines: immunosuppression may raise infection risk.

Moderate Interactions (Monitor Closely): - Warfarin: irinotecan may affect INR and bleeding risk. - Anticholinergic agents: can exacerbate cholinergic syndrome symptoms. - Other myelosuppressive drugs: additive bone marrow suppression requires dose adjustments.